Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review
Authors' conclusion
In IVIG-resistant KD, ANK was effective in controlling systemic inflammation, although more data are needed to assess its efficacy on coronary outcomes.
Study context
- Population
- Patients with intravenous immunoglobulins (IVIG)-resistant Kawasaki disease treated with anakinra32 publications
- Participants
- 81 patients
- Outcome
- Resolution of fever and systemic inflammation with ANK
Methodological detailsPRISMA 2020, all study designs eligible, Search of PubMed, Embase, Web of Science, Cochrane Library, Emcare, Academic Search Premier and Google Scholar from inception to 9 October 2025
- PRISMA 2020
- All study designs eligible
- Search of PubMed, Embase, Web of Science, Cochrane Library, Emcare, Academic Search Premier and Google Scholar from inception to 9 October 2025
Main finding
As reported in the abstract
Anakinra (ANK)
94.9%
Safety
- No serious safety concerns were identified
Original publication
Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review. RMD Open. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →